| Document |
Document Title |
|
WO/2023/074869A1 |
The present invention addresses the problem of providing a method for evaluating the risk of stomach cancer onset. Specifically, the present invention is a method for evaluating the risk of stomach cancer onset, wherein the risk of stoma...
|
|
WO/2023/071859A1 |
The present invention relates to the technical field of medications, and particularly relates to a pharmaceutical composition capable of effectively preventing an SN triple bond structure compound from being deactivated, and enhancing ta...
|
|
WO/2023/076332A1 |
The present invention relates to the development of a subcutaneous formulation of a combination of nucleoside, Gemcitabine and Zebularine. For immediate release formulation gemcitabine and zebularine may be formulated in saline solution....
|
|
WO/2023/076096A1 |
The invention provides novel approaches to the prevention and treatment of the respiratory or non-respiratory infections and effects of mild to severe cytokine storms including multiorgan effects as well as the reduction in mortality. Mo...
|
|
WO/2023/067138A1 |
The present invention relates to novel uses of gamma delta T-cell activating antibodies, in particular uses of such antibodies in patients that are also being treated, or have recently been treated, with aminobisphosphonates, or other in...
|
|
WO/2023/068858A1 |
This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or...
|
|
WO/2023/065550A1 |
The present invention provides a polydisulfide polypeptide nanoparticle, which is a nanoparticle formed by assembling a disulfide heterocyclic compound and a polypeptide drug. The disulfide heterocyclic compound has a structure as shown ...
|
|
WO/2023/068328A1 |
The purpose of the present invention is to discover and provide a novel ubiquitin drug discovery technique whereby it becomes possible to induce a ubiquitin-proteasome system from a target peptide that is difficult to be ubiquitinated an...
|
|
WO/2023/068104A1 |
The present invention provides a medical agent improving antitumor effect.
|
|
WO/2023/067058A1 |
The invention relates generally to cancer treatments involving an epigenetic agent which promotes the effectiveness of a kinase inhibitor.
|
|
WO/2023/068404A1 |
The present invention relates to a method for providing information for selecting a treatment drug for an EML4-ALK-positive non-small cell lung cancer patient, and a composition for treating ALK inhibitor-resistant non-small cell lung ca...
|
|
WO/2023/068376A1 |
Provided is a pharmaceutical composition which is effective as an anti-cancer immunostimulating therapy. Said pharmaceutical composition has a compound set forth in general formula (I) or a salt thereof as an active ingredient {in the fo...
|
|
WO/2023/069152A1 |
The present invention includes methods for treating a proliferative disorder in a subject with mutated or constitutively active FLT3 in a subject relapsed/refractory to one or more prior tyrosine kinase inhibitors comprising: obtaining a...
|
|
WO/2023/068297A1 |
The present invention addresses the problem of providing a composition that is used in order to prevent or suppress refeeding syndrome. Provided as a solution to the problem is a composition that is used to prevent or suppress refeeding ...
|
|
WO/2023/068325A1 |
Provided is an anticancer agent containing nitrogen 15 and also containing a substance that is accumulated specifically in cancer cells. Also provided is a method for killing cancer cells in vitro, said method comprising accumulating nit...
|
|
WO/2023/067485A1 |
Present invention relates to combination of Apremilast or pharmaceutically acceptable salts thereof and Rifaximin or its polymorphs or isomers or pharmaceutically acceptable salts. Present invention provides the pharmaceutical compositio...
|
|
WO/2023/067483A1 |
The invention relates to a pharmaceutical combination comprising an MDM2 inhibitor, a BCL2 inhibitor and a hypomethylating agent. The present invention also relates to methods of treating haematological malignancies involving said combin...
|
|
WO/2023/068176A1 |
Provided are: a neuron proliferation promoting agent containing, as an active ingredient, an inhibitor of miR-191-5p or an expression inhibitor of miR-191-5p; a prophylactic or therapeutic agent for Alzheimer's disease or depression, the...
|
|
WO/2023/069037A1 |
The present invention relates to ophthalmic formulations for the treatment of presbyopia, dry eye disease and computer vision syndrome, and a method for preparing the same. The objective of the present invention is to treat symptoms caus...
|
|
WO/2023/068366A1 |
The present invention addresses mainly the problem of providing a novel composition or pharmaceutical that targets the mitochondrial network etc. and exhibits excellent anticancer activity while having a minimal effect on normal cells.ã€...
|
|
WO/2023/068226A1 |
The present invention provides: an antibody that specifically binds to CD37-positive tumor cells such as B-cell malignant lymphoma; an antibody-drug conjugate that contains said antibody; a pharmaceutical composition that employs said an...
|
|
WO/2023/067501A1 |
In one aspect, methods are provided for treating a human subject having or susceptible to mucositis, comprising administering to the human subject an effective amount of EC-18, thereby treating or preventing the mucositis.
|
|
WO/2023/065551A1 |
Provided in the present invention are an aggregate and a preparation method therefor, and an insulin oral preparation. Specifically provided is an aggregate, which is an aggregate formed by means of assembling a chalcogen heterocyclic co...
|
|
WO/2023/061446A1 |
The present invention belongs to the field of medicine. Provided is a pharmaceutical composition for enhancing the anti-tumor effect of an EZH2 inhibitor. The pharmaceutical composition comprises an EZH2 inhibitor and a PPARα agonist, w...
|
|
WO/2023/063154A1 |
[Problem] To provide: a novel tracer drug for radioactive PET diagnosis that has high accumulation properties and retention properties at a tumor site, and an efficient production method (labeling synthesis method) of the tracer drug. [S...
|
|
WO/2023/063827A1 |
The invention relates to a bismuth containing composition for use in prophylaxis or treatment of an infection by Pseudomonas (P.) aeruginosa. The invention further relates to the concomitant use of a bismuth containing compound and an an...
|
|
WO/2023/063026A1 |
A problem addressed by the present invention is to provide an anti-MerTK antibody that has a tumor-suppressing effect and does not tend to cause ocular toxicity.　The present invention provides an antibody or a fragment thereof that bin...
|
|
WO/2023/062149A1 |
The present invention concerns a new method based on the combination of a particular osmotic swelling, an adapted and controlled plasma membrane lysis and removal, to produce said giant extracellular organelles vesicles, and use of said ...
|
|
WO/2023/063325A1 |
The purpose of the present invention is to provide therapeutic and preventive agents for COVID-19. The present invention provides a therapeutic or preventive composition for COVID-19, said composition containing an ADAM10 inhibitor. The ...
|
|
WO/2023/061457A1 |
Disclosed in the present invention are an antibody-drug conjugate, a pharmaceutical composition comprising the antibody-drug conjugate, and an application of the antibody-drug conjugate and the pharmaceutical composition in preparation o...
|
|
WO/2023/063400A1 |
Provided is a transgenic non-human animal enabling an analysis of an evaluation of proteasome function and activity on an individual basis. The present invention relates to a transgenic non-human animal and the like with an attenuated pr...
|
|
WO/2023/020212A9 |
Use of a DRD2 inhibitor in the preparation of a drug for treating diseases associated with liver fibrosis. In one embodiment, the DRD2 inhibitor is Fluphenazine (Flu) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/063784A1 |
The present invention relates to a composition for combination therapy, comprising a 2,3,5-substituted thiophene compound, has an activity of inhibiting cancer cells associated with leukemia that is superior to that of treatment individu...
|
|
WO/2023/062222A1 |
The present invention relates to an association of a Faecalibacterium prausnitzii bacterial strain deposited to the CNCM under the accession number I-4573; and at least one immune checkpoint inhibitor, in particular at least one monoclon...
|
|
WO/2023/061554A1 |
The present invention relates to the use of 5-Hydroxymethylfurfural (5-HMF) for prevention and/or treatment of conditions or diseases, respectively, associated with mitochondrial dysfunction as well as corresponding treatment methods.
|
|
WO/2023/062159A1 |
The present invention relates to the association of at least one bacterial strain of the species Enterococcus faecalis and an anti-inflammatory agent, a composition comprising same, and the uses thereof as a medicament, in particular for...
|
|
WO/2023/064847A1 |
Provided herein are methods of treating a trauma patient, the method including: (a) administering a HDAC inhibitor to the trauma patient; and (b) administering a GRK2 inhibitor to the trauma patient, wherein the treatment prevents, reduc...
|
|
WO/2023/064819A1 |
Provided herein are methods of treating a subject having epidermolysis bullosa, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amniotic fluid substantially free of en...
|
|
WO/2023/062516A1 |
Preparations and forms of 2-deoxy-D-glucose (2-DG) for use in the treatment or prevention of a viral disease, collaboratively in the treatment of cancer with other cancer treatments, and in a natural preparation with natural minerals to ...
|
|
WO/2023/062354A2 |
The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and na...
|
|
WO/2023/057613A1 |
The present invention relates to benzimidazole derivatives and pharmaceutical compositions comprising such benzimidazole derivatives, for use in the treatment or prevention of a histiocytosis or a craniopharyngioma.
|
|
WO/2023/057386A1 |
The present application relates to compositions comprising sialic acid and/or fucose to enhance cognitive function by promoting differentiation of oligodendrocyte precursor cells into mature, myelinating oligodendrocytes.
|
|
WO/2023/059728A1 |
The present invention concerns methods of treating and/or preventing sexual dysfunction, wherein the sexual dysfunction is associated with one or more mental health conditions, the method using a pharmaceutical composition comprising the...
|
|
WO/2023/060227A1 |
The present invention provides methods for selecting a cancer patient who is YAP1 and/or TAZ nuclear positive, and methods for treating cancer in a cancer patient who is YAP1 and/or TAZ nuclear positive, and administering to the patient ...
|
|
WO/2023/058987A1 |
The present invention relates to a pharmaceutical composition for preventing or treating viral infectious diseases, containing efavirenz and fluoxetine as active ingredients. It has been identified that when a complex, mixture or combina...
|
|
WO/2023/057819A1 |
The disclosure is in part directed to a method of treating a cancer in a patient in need thereof, comprising administering to the patient an effective amount of a HSF1 pathway inhibitor, wherein the cancer comprises solid tumors identifi...
|
|
WO/2023/057882A1 |
This disclosure relates to a method for treating cancer by administering a compound of Formula (I) in combination with a PD-1 axis binding antagonist to a subject in need thereof.
|
|
WO/2023/059703A1 |
Provided are methods for treating various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA), with the JAK1 inhibitor, upadacitinib free base or pharmaceutically acceptable salt thereof. In various aspects, ...
|
|
WO/2023/057879A1 |
Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior...
|
|
WO/2023/057109A1 |
The present invention relates to the medical-pharmaceutical field of therapy of inflammatory diseases of in particular the human ear and more particularly of various forms of otitis such as otitis media. The invention particularly relate...
|
